MILLENNIUM DEAL WORTH AS MUCH AS $255.5M

Millennium Pharmaceuticals Inc. said it agreed to sell additional rights to its Integrilin heart drug to Schering-Plough Corp. in return for $35.5 million in cash and at least $170 million in royalties. The deal, aimed at minimizing financial risk to Millennium, also lessens the Cambridge biotechnology company's control over what has been one of its most important drugs and represents a major strategic move by its new chief executive.

Schering-Plough will also pay $45 million to $50 million to buy drug inventories, the companies said.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=8ffa0242f4a4b114&cat=6dcd932030878143)